JMP Securities analyst Jonathan Wolleben has reiterated their bullish stance on PHVS stock, giving a Buy rating today.
Jonathan Wolleben has given his Buy rating due to a combination of factors, including Pharvaris’s successful completion of target enrollment in its Phase 3 RAPIDe-3 trial for the on-demand treatment of HAE attacks. This milestone positions the company well for future data releases, which are anticipated to be significant in 2026. Additionally, Pharvaris’s financial health is robust, with $293 million in cash, providing a sufficient runway into the third quarter of 2026.
Wolleben also highlights the potential of deucrictibant, Pharvaris’s oral treatment option, which could offer a convenient and effective alternative to current injectable therapies. The analyst notes that the market could expand significantly if the oral option is adopted broadly, as it addresses an unmet need for both on-demand and prophylactic treatment of HAE attacks. With expected U.S. launches in 2027 and 2028, peak sales are projected to reach approximately $600 million and $1.7 billion for the acute and prophylactic settings, respectively.
In another report released today, Morgan Stanley also maintained a Buy rating on the stock with a $34.00 price target.